• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Targeting Host Kinases for Hepatitis C Treatment

by katie.lowery / Thursday, 12 June 2014 / Published in Emerging Targets

Traditionally, treatment of viruses has focused on targeting the viral proteins, however recent research has given rise to the idea of treating viruses by targeting host factors.  The most advanced of these for Hepatitis C virus (HCV) is Alispovir, currently in Phase III clinical trials, which inhibits the peptidyl-prolyl isomerase activity of cyclophilin A.  Building on this idea, researchers from the Tokyo Metropolitan Institute of Medical Science are working to develop a small-molecule inhibitor of cyclin-dependent kinases as a novel treatment for HCV.  Their work is published this month in Antiviral Research. 

 

HCV is a causative agent of chronic hepatitis, and persistent HCV infection often leads to the development of severe liver diseases, including cirrhosis and hepatocellular carcinoma.  As an estimated 170 million people worldwide are infected with HCV, the virus is an increasing concern for global public health. There are six different genotypes of HCV, with type 1 accounting for nearly 60% of global infections. The current standard therapy for HCV is a treatment of pegylated interferon and ribavirin.  However this treatment can be ineffective for several of the HCV genotypes, including the most commonly occurring type 1.  Furthermore, the treatment is often associated with serious side effects and high costs.

 

Hoping to develop a more comprehensive treatment, researchers focused on disrupting host mechanisms necessary for HCV replication.  Specifically they focused on retinoblastoma protein (Rb) which plays a major role in controlling the G1 to S phase transition. 

 

Early in G1, Rb binds to the E2F transcription factors and blocks the E2F transactivation domains, recruiting transcriptional co-repressors and resulting in the repression of E2F-responsive promoters.  Given that S phase facilitates both replication and translation of HCV, Rb is a negative regulator of two mechanisms necessary for HCV replication.  Rb, however, is inactivated during normal cell progression.  Progression through the cell cycle requires growth signals that lead to the activation of several cyclin-dependent kinases (CDK).  CDKs phosphorylate Rb at multiple sites to suppress the repressive function of Rb. 

 

In order to restore the repressive function of Rb researchers tested several CDK inhibitors.  Their results show that CDK inhibitors suppress HCV replication in vitro and in vivo.  Furthermore, they identify an interphase CDK, CDK4, as a host factor that is required for efficient HCV replication, suggesting a highly specific potential target for HCV therapy. Ongoing work on development of CDK inhibitors as anticancer drugs could potentially be leveraged to accelerate the development of more effective HCV treatments.  A recent review of targeting host factors for HCV treatment can be found here.   

 

 

Tagged under: Transcreener ADP Kinase Assay

What you can read next

malignant adenocarcinoma could be treated by NUDT5 Inhibitors
Exploring the Use of NUDT5 Inhibitors to Treat Breast Cancer
Sialyltransferases: Sugar Makes the Medicine Go Down?
Phosphodiesterase Inhibitors: Increasing Immunity and Improving Antitumor Therapies

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...
  • Scientist Studying ALKPK1

    The Role of ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP